PLL Therapeutics obtains authorization to start phase I/II trial in Australia for patients with Amyotrophic Lateral Sclerosis (ALS)
Dr. Kechairi strengthens clinical team to advance PLL Therapeutics’ autoimmune and neurodegenerative diseases pipeline and enter phase 1 clinical trials with lead candidate for Amyotrophic Lateral Sclerosis (ALS)...